High expression of PU.1 is associated with Her‑2 and shorter survival in patients with breast cancer

  • Authors:
    • Jing Lin
    • Wei Liu
    • Tian Luan
    • Lili Yuan
    • Wei Jiang
    • Huilong Cai
    • Weiguang Yuan
    • Yuwen Wang
    • Qingyuan Zhang
    • Lihong Wang
  • View Affiliations

  • Published online on: October 18, 2017     https://doi.org/10.3892/ol.2017.7204
  • Pages: 8220-8226
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The transcription factor PU.1 was previously identified as an oncogene or a tumor suppressor in different types of leukemia. The aim of the present study was to investigate the expression of PU.1 in breast cancer and to analyze its association with clinical features and prognosis. Immunohistochemistry was used to determine PU.1 expression in breast cancer tissue microarrays and paraffin‑embedded sections. The association between PU.1 expression and clinicopathological factors was assessed by using chi‑square test. The survival analysis of patients was conducted by using Kaplan‑Meier analysis and log‑rank tests. Cox regression was utilized for univariate and multivariate analyses of prognostic factors. The results indicated that the expression level of PU.1 protein in breast cancer samples was significantly higher compared with normal breast tissues (P=2.63x10‑8). Furthermore, the level of PU.1 expression was detected to be positively associated with androgen receptor (P=0.027) and human epidermal growth factor receptor 2 status (P=2.03x10‑21) as well as molecular subtype (P=3.51x10‑11). Furthermore, patients with negative PU.1 expression had longer OR compared with those with positive PU.1 expression (P=3.67x10‑4). Multivariate Cox regression analysis revealed that PU.1 expression level and tumor‑node‑metastasis stage were independent prognostic factors for overall survival (P=0.034 and P=0.018, respectively). Therefore, PU.1 protein expression may contribute to breast cancer progression and may be a valuable molecular marker to predict the prognosis of patients with breast cancer.
View Figures
View References

Related Articles

Journal Cover

December-2017
Volume 14 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lin J, Liu W, Luan T, Yuan L, Jiang W, Cai H, Yuan W, Wang Y, Zhang Q, Wang L, Wang L, et al: High expression of PU.1 is associated with Her‑2 and shorter survival in patients with breast cancer. Oncol Lett 14: 8220-8226, 2017
APA
Lin, J., Liu, W., Luan, T., Yuan, L., Jiang, W., Cai, H. ... Wang, L. (2017). High expression of PU.1 is associated with Her‑2 and shorter survival in patients with breast cancer. Oncology Letters, 14, 8220-8226. https://doi.org/10.3892/ol.2017.7204
MLA
Lin, J., Liu, W., Luan, T., Yuan, L., Jiang, W., Cai, H., Yuan, W., Wang, Y., Zhang, Q., Wang, L."High expression of PU.1 is associated with Her‑2 and shorter survival in patients with breast cancer". Oncology Letters 14.6 (2017): 8220-8226.
Chicago
Lin, J., Liu, W., Luan, T., Yuan, L., Jiang, W., Cai, H., Yuan, W., Wang, Y., Zhang, Q., Wang, L."High expression of PU.1 is associated with Her‑2 and shorter survival in patients with breast cancer". Oncology Letters 14, no. 6 (2017): 8220-8226. https://doi.org/10.3892/ol.2017.7204